Kecellitics Biotech

Kecellitics Biotech is a clinical-stage biotechnology company specializing in precision oncology through its proprietary i-CR® (integrated Cancer Response) platform. The company utilizes patient-derived organoids (PDO) and high-throughput screening to identify optimal therapeutic candidates and develop a pipeline of targeted therapies. Their primary focus is on DNA Damage Response (DDR) and synthetic lethality pathways to treat various solid tumors. Headquartered in Shanghai with R&D facilities in the United States, Kecellitics aims to bridge the gap between laboratory discovery and clinical efficacy. The company's lead program, K001, is an ATR inhibitor currently in clinical development for advanced solid tumors. By integrating functional genomics with organoid technology, Kecellitics seeks to improve the success rate of drug development and provide personalized treatment options for cancer patients.